Healthtech SMEs looking to upscale their US business have a limited time left to apply to the 2023 ABHI US Accelerator, developed by the Association of British HealthTech Industries (ABHI).
Now in its fifth year, the ABHI US Accelerator is aimed at UK medical device, diagnostic and digital health companies looking to tap into opportunities to expand their reach cross-Atlantic. The 12-month programme of support provides them with the opportunity to define and strengthen their US strategy, de-risk market entry and grow their US business by utilising ABHI’s advice, expertise, and connections within the country.
The annual programme, conducted in partnership with the Dell Medical School in Austin, Texas provides access to ABHI’s US network, including in-market specialists to guide companies on specific issues, including regulation, reimbursement, and technology appraisal. The programme also facilitates introductions to hospital, clinical champions, and supply chain leaders, enabling companies to liaise directly with decision-makers to discuss their products and services.
Successful applicants will have week-long trade missions across the US, providing them with opportunities to engage with stakeholders for their individual company objectives and present proven UK healthtech to new clients.
With 60% of places already filled, companies keen to take advantage of the offer have until the 31st October to apply for the ABHI’s 2023 cohort.
Paul Benton, managing director, international, ABHI said: “We are excited to have expanded our 2023 programme to support even more companies grow their US business by taking advantage of the strong network of hospital, clinical and supply chain leaders we have built across the country. Wrapped around this offer is a dedicated mission programme to key US states, with an exceptional set of mentors on hand to support. It is often described by companies within the programme as being their most cost-effective marketing spend ever.”
As part of the programme, ABHI secretariat work hand-in-hand with each company, setting milestones and goals that support company growth. They support early stage, pre-FDA approved companies, helping them to navigate the FDA process, develop market research, and set up trial sites, all the way up to more established SME’s with pre-existing sales in the US.
Richard Jones, president and chief strategy officer at C2-Ai, a member of the 2022 cohort, said: “In simple terms, the ABHI Accelerator has been the most cost-effective marketing spend ever. Our approach to reducing cost and harm across hospitals is unique and gaining huge traction globally. However, the ABHI opens doors to have discussions with senior leaders with the leading hospitals in the regions they visit. That gives us a platform to engage with people that might otherwise be difficult to access. It's a complete no-brainer to sign up for next year.”
Nick de Pennington, founder & CEO, Ufonia who have rejoined the programme for a second year, added: “It has been quite amazing to have this level of access and engagement from the senior leadership teams of some of the largest healthcare organisations within the US. The ABHI US Accelerator opportunity has been invaluable for our company, allowing us to make connections and understand the needs of end users and decision makers, so that we can effectively deploy and scale-up our business in the US market.”
